Navigation Links
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
Date:5/31/2008

decades(3).

"These results represent a tremendous advance for women hoping to prevent the return of their cancer," said David Epstein, President and CEO of Novartis Oncology. "We continue to explore the anticancer benefit of Zometa in a large clinical program with nearly 20,000 patients in 10 trials worldwide. We anticipate additional results over the next two to three years."

The ABCSG-12 study, in which women were treated for three years and observed for an additional two years, demonstrated that the addition of Zometa to hormone therapy (tamoxifen or anastrozole) significantly prolonged both disease-free survival and recurrence-free survival. With Zometa, the risk of disease-free survival events (which include death from any cause) fell by 36% (P=0.01), compared to hormone therapy alone. Furthermore, the risk of recurrence-free survival events fell by 35% (P=0.015) with Zometa, compared to hormone therapy alone. A positive but non-significant trend toward an overall survival benefit was also seen in patients who received Zometa(1).

Zometa is the world's leading treatment for the prevention or delay of skeletal-related events (SREs) in patients with advanced malignancies involving bone across a broad range of tumors. Laboratory research had suggested that Zometa may also help protect patients from the spread of cancer to other parts of the body (distant metastatic sites) and help keep patients recurrence-free.

Zometa slows the bone-destroying effect that occurs with bone metastases by fighting abnormal activation of osteoclasts, cells that normally break down old bone, and osteoblasts, cells that normally build new bone. Growth factors produced by cancer cells overstimulate osteoclasts and osteoblasts, causing excessive erosion of bone and/or the abnormal buildup of new but unstable bone.

Laboratory research has suggested that Zometa may also have anticancer effects, including helping to protect against the return and spread of c
'/>"/>

SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
2. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
3. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
4. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
5. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
6. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
7. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
8. Video: New Research Discovers Independent Brain Networks Control Human Walking
9. BioElectronics Announces Major Clinical Trials
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...c. 4 Suneva Medical, a privately-h...ced the appointment of Philip Ranker as Vice Presi...r. Ranker will lead all Suneva Medical,s general a...ounting, IT, IR, administration and human resource...agement team. ,, "One of my key objectives as ...
(Date:12/4/2009)... Drs. Neal Shore and E. David Crawf...n (PSA) recurrence from the additional analysis of...te in a Phase III pivotal study of FIRMAGON® ...olide in prostate cancer patients during the first...received FIRMAGON 240/80 mg/month had a recurrence...
(Date:12/3/2009)... Allen Medical Systems, ...RC ), today announced the launch of its new Allen ...business website www.AllenAmatech.com . ,, ... identity and includes an online version of the ne...design specifications for the products. "We hope t...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 1Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 2Accelerated Development of New Treatment for Multi Drug Resistant Tuberculosis 3A TB Alliance and Tibotec Announce Unique Partnership to Develop TMC20 49213 3AMDL CEO Featured in CEOCFO Magazine 3B Details Progress on DR 70 International Commercialization Strategy 26 Confidence in FY2009 Financial Forecast 49211 1AMDL CEO Featured in CEOCFO Magazine 3B Details Progress on DR 70 International Commercialization Strategy 26 Confidence in FY2009 Financial Forecast 49211 2AMDL CEO Featured in CEOCFO Magazine 3B Details Progress on DR 70 International Commercialization Strategy 26 Confidence in FY2009 Financial Forecast 49211 3Hartford grants increase support for geriatric social work training 49209 1Hartford grants increase support for geriatric social work training 49209 2Hartford grants increase support for geriatric social work training 49209 3
...ne in the Treatment of Patients with Relapsed/Ref...ented Tomorrow, Tuesday, June 3rd at 12:0...rmaceuticals,Inc. (Nasdaq: KERX ) today announced...ave been selected for both poster presentation and...al Oncology Meeting,currently taking place in Chic...
...erican Society of Clinical Oncology (ASCO),annual ...vival vs. external c...c.,(Nasdaq: IDMI ) today announced follow-up resu...t the product candidate was well tolerated, induce...sponses, and showed a,positive survival trend in H...
Other Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 2Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 3Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 4Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois 5IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients 2IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients 3IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients 4
(Date:12/4/2009)...earchers, from the School of Medicine,s Department...ys by which products of lipid peroxidation and som...abolized. The pathways were identified by a combin.... The findings shed new light on the mechanism of ... also known as "the date rape drug." The manuscrip...
(Date:12/4/2009)...immediately or 3 weeks later, study shows , ... surgical repair or reconstruction of multiple-lig..., a new study has found. , Multiple-ligament kn...s that can occur in high-impact car crashes or in ...y to repair these injuries hasn,t been definitivel...
(Date:12/4/2009)...s Historic Effort but Points out Potential Risk if...ealth Care Reform ,, NEW YORK, Dec. 4 /PRNews...edicine today published a Perspective opinion pi...Irwin Redlener, M.D., president, Children,s Health...reparedness and Professor of Clinical Population &...
(Date:12/4/2009)...ookah, research shows , , FRIDAY, Dec. 4... cigarettes for smoking tobacco, researchers say. ...co with a water pipe inhale carbon monoxide and ni...and nicotine addiction. , The study included 31...ng a water pipe and a single cigarette. After each...
(Date:12/4/2009)...PRNewswire-FirstCall/ -- When the spread of H1N1 f... of Health Services needed to get more information...n Sonic Foundry, Inc. (Nasdaq: SOFO ), the reco... knowledge management, for a live webinar in which...h Services, will share how in-house webcasting rel...
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:Water Pipes No Safer Than Cigarettes 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3
...o be the most powerful indicator of heart disease....reased levels of total amount cholesterol in blood...tein)or 'bad' cholesterol and HDL(High-Density Lip...d molecule called// apolipoprotein, which they bel...
...s the world over, with India being touted as the "...erious diseases that diabetics can be affected wit...the deterioration of nerves in the body. A diabeti...abetes will develop// neuropathy. A study by ...
...uing the field of medicine and patients are now de... medical error happens. However, doctors are often...ey do not care. In fact, doctors confessed to bein...ng patients, doctors, and// patients and doctors t...
...eceived a patient, a two-month-old baby with white...are disease caused due to a deficiency of lipoprot... 10 million children. Doctors said that the baby w...his condition could be either due to// ‘familial l...
...a common genetic mutation called C150T transition ...scovering a "fountain of youth". This genetic muta...lood cells, in a study of a group of 52 Italian ce...he age// of 99. Mitochondria are so-called "o...
...ersity of Rochester, New York suggests that the ac...mmatory and anti-coagulant properties,which until ...also help reduce the damage caused by stroke. Rese...ng apoptosis, a form of programmed cell death. The...
Other Medicine News:
Disposable Lacrimal Dilators
Reusable Double Dilators
Skin Tone External Eyelid Weights
Contour Design Eyelid Implants (Gold)
Medicine Products: